Ironwood Pharmaceuticals (NASDAQ:IRWD) Issues Quarterly Earnings Results

Ironwood Pharmaceuticals (NASDAQ:IRWD) announced its quarterly earnings data on Thursday. The biotechnology company reported $0.24 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.01), FiscalAI reports. The company had revenue of $106.51 million during the quarter, compared to analyst estimates of $92.11 million. Ironwood Pharmaceuticals had a net margin of 28.26% and a negative return on equity of 37.48%.

Here are the key takeaways from Ironwood Pharmaceuticals’ conference call:

• LINZESS delivered a standout Q1 with 97% year?over?year U.S. net sales growth ($272.5M) driven by improved net price and 5% prescription demand growth, and management reiterated full?year LINZESS U.S. net sales guidance of $1.125–$1.175 billion.
• The FDA has accepted a supplemental NDA for LINZESS in functional constipation for ages 2–5 with a priority review and PDUFA date of May 24, 2026, which could broaden the pediatric label if approved.
• Apraglutide is on track to initiate the confirmatory Phase III STARS 2 trial in Q2 (planned 124 patients, same primary endpoint at week 24); prior STARS data showed a ~twofold reduction in parenteral support and ~20% of patients in the long?term extension achieved enteral autonomy, supporting a potential U.S. peak net?sales opportunity of >$700M.
• Strong Q1 financials—GAAP net income of $40.8M, adjusted EBITDA of $76.7M, cash of $220.5M and plans to repay the June convertible note—management expects 2026 adjusted EBITDA >$300M and to reduce net debt to ~1x EBITDA by year?end.
• Q1 net?price gains were driven largely by elimination of inflationary rebates and favorable gross?to?net timing, and management expects an R&D ramp for STARS 2; these factors create execution and pricing risk that could pressure results if rebate dynamics or trial costs differ from assumptions.

Ironwood Pharmaceuticals Trading Up 1.2%

NASDAQ IRWD traded up $0.05 during trading on Friday, hitting $4.22. 2,547,764 shares of the company’s stock were exchanged, compared to its average volume of 2,216,940. The company has a market cap of $688.11 million, a PE ratio of 7.03 and a beta of 0.29. Ironwood Pharmaceuticals has a fifty-two week low of $0.53 and a fifty-two week high of $5.78. The stock’s 50 day moving average price is $3.70 and its two-hundred day moving average price is $3.63.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on IRWD shares. Wall Street Zen downgraded Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday. Citizens Jmp increased their price objective on shares of Ironwood Pharmaceuticals from $8.00 to $10.00 and gave the stock a “market outperform” rating in a research note on Thursday, February 26th. Jefferies Financial Group reissued a “hold” rating and issued a $3.70 target price on shares of Ironwood Pharmaceuticals in a report on Thursday, February 26th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a report on Monday, April 27th. Finally, Zacks Research lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Ironwood Pharmaceuticals has an average rating of “Hold” and a consensus target price of $6.23.

Insider Buying and Selling at Ironwood Pharmaceuticals

In related news, Director Alexander J. Denner sold 6,730,800 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $3.05, for a total transaction of $20,528,940.00. Following the sale, the director directly owned 9,188,635 shares of the company’s stock, valued at approximately $28,025,336.75. The trade was a 42.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 12.70% of the company’s stock.

Institutional Trading of Ironwood Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Integrated Wealth Concepts LLC increased its holdings in shares of Ironwood Pharmaceuticals by 21.4% during the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock worth $25,000 after buying an additional 3,406 shares in the last quarter. Captrust Financial Advisors acquired a new position in Ironwood Pharmaceuticals in the 2nd quarter worth about $32,000. Jump Financial LLC bought a new position in Ironwood Pharmaceuticals in the fourth quarter valued at about $34,000. Cibc World Markets Corp bought a new position in Ironwood Pharmaceuticals in the fourth quarter valued at about $36,000. Finally, Vise Technologies Inc. acquired a new stake in shares of Ironwood Pharmaceuticals during the third quarter valued at about $39,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial?stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.